Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sodium aspirin

This article was originally published in The Tan Sheet

Executive Summary

FDA denies request by Pharmacontrol to include sodium aspirin in the internal analgesics monograph as a subset of aspirin or as a separate ingredient. In a June 4 letter, FDA stated that "aspirin and sodium aspirin are chemically related but are not identical," and asked the firm to submit information on the marketing history of sodium aspirin in other countries and on sodium aspirin's inclusion in any pharmacopeia. Pharmacontrol has been developing soluble sodium aspirin for nearly a decade.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS081591

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel